Abstract: Disclosed herein are antibodies that specifically bind human erythroferrone and assay methods for detecting and/or measuring human erythroferrone, analogs of human erythroferrone, and fragments thereof. Specifically, the methods comprising using an antibody as a capture reagent and an antibody as a detection reagent for detecting or measuring a detectable label of the at least one detection reagent bound to the erythroferrone polypeptide that is bound to the capture reagent. Further disclosed are the sequences of antibodies.

Abstract: Disclosed herein are antibodies that specifically bind human erythroferrone and assay methods for detecting and/or measuring human erythroferrone, analogs of human erythroferrone, and fragments thereof. Specifically, the methods comprising using an antibody as a capture reagent and an antibody as a detection reagent for detecting or measuring a detectable label of the at least one detection reagent bound to the erythroferrone polypeptide that is bound to the capture reagent. Further disclosed are the sequences of antibodies.

Abstract: Disclosed herein are polypeptides which are capable of modulating the amount of hepcidin in subjects. Also disclosed are compositions and methods for treating diseases and disorders of iron metabolism.

Abstract: Disclosed herein are peptides which exhibit hepcidin activity and methods of making and using thereof.

Abstract: Disclosed herein S-alkylated hepcidin peptides and methods of making and using thereof. In some embodiments, the present invention is directed to an S-alkylated hepcidin peptide having the following Structural Formula IA or IB. In some embodiments, the present invention is directed to a composition comprising at least one S-alkylated hepcidin peptide of the present invention. In some embodiments, the present invention is directed to a method of binding a ferroportin or inducing ferroportin internalization and degradation which comprises contacting the ferroportin with at least one S-alkylated hepcidin peptide of the present invention. In some embodiments, the present invention is directed to a kit comprising at least one S-alkylated hepcidin peptide.

Abstract: Disclosed herein are peptides which exhibit hepcidin activity and methods of making and using thereof.

Abstract: Disclosed herein are polypeptides which are capable of modulating the amount of hepcidin in subjects. Also disclosed are compositions and methods for treating diseases and disorders of iron metabolism.

Abstract: Disclosed herein are peptides which exhibit hepcidin activity and methods of making and using thereof.

Abstract: Disclosed herein are peptides which exhibit hepcidin activity and methods of making and using thereof.

Abstract: Disclosed herein are peptides which exhibit hepcidin activity and methods of making and using thereof.

Abstract: Disclosed herein are peptides which exhibit hepcidin activity and methods of making and using thereof.

Abstract: In accordance with the present invention, recombinant human PBEF has been produced in order to study its ability to stimulate the transcription of the key cytokine mediators of labor induction, using the amnion-like epithelial (WISH) cell line and fetal membrane explants. As a result of these studies, it has been determined that PBEF is a good indicator of initiation of labor. This makes PBEF a useful marker, especially for the identification of subjects who have initiated preterm labor. Accordingly, methods for the identification of subjects who have commenced labor are provided. In addition, methods are also provided for blocking labor, as well as compositions useful therefor. This is accomplished by blocking the production of PBEF or by blocking the action of PBEF.

Abstract: In accordance with the present invention, recombinant human PBEF has been produced in order to study its ability to stimulate the transcription of the key cytokine mediators of labor induction, using the amnion-like epithelial (WISH) cell line and fetal membrane explants. As a result of these studies, it has been determined that PBEF is a good indicator of initiation of labor. This makes PBEF a useful marker, especially for the identification of subjects who have initiated preterm labor. Accordingly, methods for the identification of subjects who have commenced labor are provided. In addition, methods are also provided for blocking labor, as well as compositions useful therefor. This is accomplished by blocking the production of PBEF or by blocking the action of PBEF.